APO RESEARCH · REPORT
mRNA Cancer Vaccines and Therapeutics
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Product & engineering
Understand the product.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Selected research
Industry Growth & Trends
Global mRNA Cancer Vaccines and Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
According to APO Research, the global mRNA Cancer Vaccines and Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global mRNA Cancer Vaccines and Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The mRNA Cancer Vaccines and Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global mRNA Cancer Vaccines and Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to mRNA Cancer Vaccines and Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global mRNA Cancer Vaccines and Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
mRNA Cancer Vaccines and Therapeutics Market by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Cancer Vaccines and Therapeutics Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
mRNA Cancer Vaccines and Therapeutics Segment by Application
Infectious Disease
Cancer
Others
mRNA Cancer Vaccines and Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Adeno Carcinomas
- Mucinous Carcinomas
- Adenosquamous Carcinomas
Applications
- Infectious Disease
- Cancer
- Others
Companies covered
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 1.5.1 North America mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (2021-2032)
2 mRNA Cancer Vaccines and Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Adeno Carcinomas
- 2.1.2 Mucinous Carcinomas
- 2.1.3 Adenosquamous Carcinomas
- 2.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 2.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global mRNA Cancer Vaccines and Therapeutics Market Size by Regions
- 2.3.1 North America mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Type (2021-2026)
3 mRNA Cancer Vaccines and Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Infectious Disease
- 3.1.2 Cancer
- 3.1.3 Others
- 3.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 3.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global mRNA Cancer Vaccines and Therapeutics Market Size by Regions
- 3.3.1 North America mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
- 4.2 mRNA Cancer Vaccines and Therapeutics Industry Drivers
- 4.3 mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges
- 4.4 mRNA Cancer Vaccines and Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by mRNA Cancer Vaccines and Therapeutics Revenue (2021-2026)
- 5.2 Global mRNA Cancer Vaccines and Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global mRNA Cancer Vaccines and Therapeutics Key Company Headquarters & Area Served
- 5.4 Global mRNA Cancer Vaccines and Therapeutics Company, Product Type & Application
- 5.5 Global mRNA Cancer Vaccines and Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global mRNA Cancer Vaccines and Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 mRNA Cancer Vaccines and Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 mRNA Cancer Vaccines and Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Moderna Therapeutics
- 6.1.1 Moderna Therapeutics Company Information
- 6.1.2 Moderna Therapeutics Business Overview
- 6.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.1.5 Moderna Therapeutics Recent Developments
- 6.2 CureVac
- 6.2.1 CureVac Company Information
- 6.2.2 CureVac Business Overview
- 6.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.2.5 CureVac Recent Developments
- 6.3 Translate Bio
- 6.3.1 Translate Bio Company Information
- 6.3.2 Translate Bio Business Overview
- 6.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.3.5 Translate Bio Recent Developments
- 6.4 BioNTech
- 6.4.1 BioNTech Company Information
- 6.4.2 BioNTech Business Overview
- 6.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.4.5 BioNTech Recent Developments
- 6.5 Sangamo Therapeutics
- 6.5.1 Sangamo Therapeutics Company Information
- 6.5.2 Sangamo Therapeutics Business Overview
- 6.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.5.5 Sangamo Therapeutics Recent Developments
- 6.6 Argos Therapeutics
- 6.6.1 Argos Therapeutics Company Information
- 6.6.2 Argos Therapeutics Business Overview
- 6.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.6.5 Argos Therapeutics Recent Developments
- 6.7 In-Cell-Art
- 6.7.1 In-Cell-Art Company Information
- 6.7.2 In-Cell-Art Business Overview
- 6.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.7.5 In-Cell-Art Recent Developments
- 6.8 eTheRNA
- 6.8.1 eTheRNA Company Information
- 6.8.2 eTheRNA Business Overview
- 6.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.8.5 eTheRNA Recent Developments
- 6.9 Ethris
- 6.9.1 Ethris Company Information
- 6.9.2 Ethris Business Overview
- 6.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.9.5 Ethris Recent Developments
- 6.10 Tiba Biotechnology
- 6.10.1 Tiba Biotechnology Company Information
- 6.10.2 Tiba Biotechnology Business Overview
- 6.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.10.5 Tiba Biotechnology Recent Developments
7 North America
- 7.1 North America mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 7.3 North America mRNA Cancer Vaccines and Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 10.3 South America mRNA Cancer Vaccines and Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst